The rules around compounded semaglutide have changed dramatically, and many clinicians are still operating on outdated assumptions from the shortage era. The short version, as of July 2026: the semaglutide shortage is resolved, large-scale compounding is no longer permissible, and the FDA has moved to close the door permanently through a proposed rule that is pending finalization.
This update explains how the regulatory picture got here, what 503A and 503B compounding actually mean, where the 2026 bulks-list decision stands, the liability risks for prescribers, and the compliant paths forward. It expands on the compounding section of our complete prescriber’s guide to GLP-1 medications for weight management, with a focus on the regulatory specifics.
When semaglutide demand exploded in 2021–2022, supply could not keep up, and the FDA placed semaglutide on its official drug shortage list. That designation is significant, because federal law permits compounding pharmacies to prepare copies of an FDA-approved drug when it is officially in shortage.
That window opened a large market. Compounded semaglutide became widely available through compounding pharmacies and telehealth platforms, typically at a fraction of the brand price. For many patients it was the only affordable or obtainable option during the shortage. But this availability was always contingent on the shortage status — a temporary legal accommodation, not a permanent pathway. When the shortage ended, so did the legal basis for mass compounding.
The shortages have been resolved. The FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in February 2025 (Drug Topics, 2025). Once a drug comes off the shortage list, the compounding accommodation winds down, and the agency set specific deadlines for pharmacies and outsourcing facilities to stop.
By 2026, the accommodation was gone: as of April 1, 2026, semaglutide and tirzepatide were absent from both the shortage list and the 503B bulks list. In practical terms, routine large-scale compounding of copies of these approved products is no longer lawful, and the FDA has signaled active enforcement. The same restrictions now apply on the dual-agonist side, as our guide to compounded tirzepatide sets out in detail. Clinicians who began prescribing during the shortage need to understand that the legal ground has shifted beneath that practice.
Understanding the current rules requires distinguishing the two kinds of compounding, because they are regulated differently.
503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients pursuant to a valid, patient-specific prescription. They operate largely under state regulation. Critically, they may not prepare a compound that is “essentially a copy” of a commercially available approved drug — but they retain the ability to prepare a genuinely patient-specific formulation when a documented individual clinical need exists.
503B outsourcing facilities are larger operations that can manufacture in bulk and distribute across state lines without patient-specific prescriptions. They register with and are inspected by the FDA and may only compound from bulk drug substances that appear on the FDA’s 503B bulks list. Because semaglutide is not on that list, 503B facilities cannot lawfully compound it from bulk unless it returns to shortage status. This 503A-versus-503B distinction is the crux of what is and is not currently allowed.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Primary oversight | State boards of pharmacy | FDA registration and inspection |
| Prescription required | Yes — valid, patient-specific | No — may produce in bulk for office stock |
| Scale and distribution | Individual patients | Bulk, including across state lines |
| Copies of approved drugs | Not permitted if “essentially a copy” | Only from substances on the 503B bulks list |
| Semaglutide status in 2026 | Narrow patient-specific formulations only, with documented clinical need | Not permitted — semaglutide is not on the bulks list |
On April 30, 2026, the FDA issued a proposed rule that would formally and permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (U.S. Food and Drug Administration, 2026). If finalized, it would prohibit 503B facilities from bulk-compounding these agents regardless of any future market conditions — effectively removing the “return to shortage” escape hatch for outsourcing facilities.
The public comment period closed on June 29, 2026. As of July 2026, the rule is proposed but not yet finalized; the FDA may finalize it as written, modify it in response to comments, or issue a revised proposal (Frier Levitt, 2026). Because this is a live, moving decision, prescribers and content should be date-stamped and re-verified against the current FDA position. The direction of travel, however, is unambiguous: the agency is working to close large-scale GLP-1 compounding for good (Pharmacy Times, 2026).
For prescribers, the risk profile of compounded semaglutide has changed as much as its legality. Prescribing or facilitating access to non-compliant compounded product can expose a clinician to regulatory action, state board scrutiny, and malpractice exposure — particularly given documented cases of contamination and dosing errors from inadequately regulated sources.
Cost is not a clinical rationale. Cost savings alone do not justify compounding when the approved product is commercially available — “it’s cheaper” is not a lawful basis. Sourcing is your responsibility. Product from unverified suppliers, foreign “research” peptides, or facilities operating outside 503A/503B rules carries both patient-safety and liability risk.
A prescriber’s safest posture is to treat the approved products as the default and to document a specific, legitimate clinical rationale in the rare cases a compliant compounded formulation is genuinely warranted. That documentation habit is the same one that protects you on patient selection and contraindication screening: the record you can point to later is what makes a decision defensible. Staying current with these shifting rules is exactly what structured programs such as IAPAM’s CME-accredited GLP-1 prescribing training are designed to support.
There are still legitimate options; they are just narrower and better documented than during the shortage.
The cleanest path is prescribing the FDA-approved products, which are now more accessible through manufacturer self-pay programs than they were even a year ago — substantially narrowing the cost gap that drove patients to compounded versions. Where coverage is worth pursuing, a disciplined prior authorization process usually decides whether the prescription is filled, and the approved product then follows a published semaglutide titration schedule rather than an improvised one.
Where a genuine, patient-specific clinical need exists — for example, a documented allergy to an excipient in the approved product, or a required dose or formulation that is not commercially available — a 503A pharmacy may still prepare an appropriate compound under a valid prescription that meets Section 503A conditions. The key is that the need must be individual and documented, not a blanket cost-driven substitution. When in doubt, verify the current FDA status and consult your state board.
Treat the FDA status as a live variable, not a settled fact. Re-check the shortage list, the 503B bulks list, and the status of the proposed rule before you rely on any compounded product — and note the date you checked in the chart. A regulatory page that was accurate last quarter may not be accurate this one.
Semaglutide and tirzepatide changed what patients expect from their providers. IAPAM’s GLP-1 certification gives you the protocols, titration schedules, monitoring parameters and side-effect management to run a medically supervised weight management program with confidence.
What the certification covers
For MD/DO, NP, APRN, PA, RN and other licensed providers
GLP-1 Essentials for Weight Loss — self-paced
3 CMEs · 3-5 hours · 24/7 access
Certified Medical Weight Management Provider™ (CWMP)
6 CMEs · 8-10 hours · 24/7 access
Questions? Call 1-866-211-6901
Largely no for routine use. With the shortage resolved, 503B facilities cannot compound semaglutide from bulk, and 503A pharmacies cannot make copies of the approved product. Narrow 503A exceptions remain for documented, patient-specific clinical needs. Always re-verify the current FDA status.
Compounding copies of an approved drug is only permitted while that drug is on the FDA shortage list. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, which ended the legal basis for large-scale compounding.
503A pharmacies compound patient-specific prescriptions under state regulation and cannot copy commercially available drugs. 503B outsourcing facilities compound in bulk under FDA oversight and may only use bulk substances on the FDA’s 503B bulks list, which no longer includes semaglutide.
On April 30, 2026, the FDA proposed a rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The comment period closed June 29, 2026, and as of July 2026 the rule is proposed but not yet finalized.
Only in narrow circumstances — a documented, patient-specific need such as an excipient allergy or an unavailable dose — through a 503A pharmacy under a valid prescription. Cost savings alone are not a lawful justification when the approved product is available.
Regulatory action, state board scrutiny, malpractice exposure, and patient-safety risks from contamination or dosing errors. Product from unverified or foreign “research” sources carries particular risk.
As of July 2026, compounded semaglutide has moved from a shortage-era mainstay to a narrow, tightly regulated exception. The shortages are resolved, large-scale compounding is no longer permissible, and the FDA’s proposed 503B bulks-list exclusion — pending finalization — would close the door permanently. Prescribers should default to the approved products, reserve compounding for genuine documented needs, and re-verify the FDA’s position regularly, because this remains a moving target.
For the full clinical and regulatory picture, see our complete prescriber’s guide to GLP-1 medications. And to prescribe within the current rules with confidence, IAPAM’s compliant GLP-1 prescribing certification — backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews — keeps your protocols current and defensible. Clinicians expanding a cash-pay practice often add aesthetic services alongside weight management; the same foundation supports Botox® training for nurse practitioners.
Explore GLP-1 Certification Training →
Disclaimer: This article is for informational and educational purposes only and does not constitute legal or medical advice. Compounding regulations are actively changing; the status described here is current as of July 2026. Always verify the current FDA position and your state board’s rules before making any prescribing or sourcing decision.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.